Trial Profile
An observational study assessing the effect of natalizumab discontinuation on cognitive functions after 1 year in multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 26 Apr 2017 New trial record